Aarey Drugs & Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
AAREYDRUGS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Aarey Drugs & Pharmaceuticals has submitted its unaudited financial results for the quarter ended June 30, 2025. Total income for the quarter stood at approximately ₹1,037.60 lakhs, down about 19.5% from ₹1,288.87 lakhs in the same quarter last year. Despite the revenue dip, profit before tax jumped sharply to ₹72.82 lakhs (from a low base of ₹13.08 lakhs in Q1 FY25), and profit after tax rose to roughly ₹57 lakhs (from about ₹12 lakhs in Q1 FY25) — a multiple-fold increase. Basic EPS for the quarter was reported at ₹0.02, compared to ₹0.04 in the year-ago quarter. The statutory auditor, Motilal & Associates LLP, issued an unqualified (clean) limited review report. The company operates in a single segment of manufacturing and trading of drugs and pharmaceuticals.
Mixed picture — topline shrank nearly 20% YoY, but the company delivered a much stronger bottom line from cost control or improved margins, lifting PAT several times over. For shareholders, the sharp profit growth on a low base is encouraging, but the steep revenue fall suggests demand weakness that warrants close watch in coming quarters.